Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses

Clinical and Translational Immunology

Volumn 4, Issue 10, 2015, Pages

  Eid, Sahar G ^a,b   Mangan, Niamh E ^c   Hertzog, Paul J ^c   Mak, Johnson ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b CSIRO   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84994486016     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2015.23     Document Type: Review

References (108)

1. Global Health Observatory data- Global summary of the AIDS epidemic. 2013. WHO. Available from http://www.who.int/hiv/data/epi_core_dec2014.pngua=1.
2. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J et al. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 2014; 345: 1254031.
3. Abdool KQ, Sibeko S, Baxter C. Preventing HIV infection in women—a global health imperative!. Clin Infect Dis 2010; 50: S122–S129.
4. Wainberg MA. AIDS: drugs that prevent HIV infection. Nature 2011; 469: 306–307.
5. Perelson AS, Essunger P, Cao Y, Vesanen M, Hrley A, Saksela K et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188–191.
6. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 1817–1826.
7. Kulkarni SP, Shah KR, Sarma KV, Mahajan AP. Clinical uncertainties, health service challenges, and ethical complexities of HIV ‘test-and-treat’: a systematic review. Am J Public Health 2013; 103: e14–e23.
8. Taiwo B, Yanik EL, Napravnik S, Ryscavage P, Koletar SL, Moore R et al. CFAR Network of Integrated Clinical Systems (CNICS) Cohort Study. Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. AIDS 2013; 27: 1593–1602.
9. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specifi c antiretroviral resistance. AIDS 2009; 23: 1035–1046.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
11. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24: 915–919.
12. Cottrell ML. Kashuba ADM. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol 2014; 54: 603–615.
13. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20: 543–551.
14. Schellenberg JJ, Plummer FA. The microbiological context of HIV resistance: vaginal microbiota and mucosal inflammation at the viral point of entry. Int J Inflam 2012; 2012: 131243.
15. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22: 1493–1501.
16. Pyles RB, Vincent KL, Baum MM, Elsom B, Miller AL, Maxwell C et al. Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS ONE 2014; 9: e93419.
17. Aldunate M, Tyssen D, Johnson A, Zakir T, Sonza S, Moench T et al. Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother 2013; 68: 2015–2025.
18. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993; 4: 165–170.
19. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504–510.
20. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971–977.
21. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007; 2: e1312.
22. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3: e1474.
23. Perotti ME, Pirovano A, Phillips DM. Carageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol Reprod 2003; 69: 933–939.
24. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977–1987.
25. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE 2008; 3: e3784.
26. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359: 463–472.
27. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioqlu E et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200: 599–608.
28. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T et al. Safety and effectiveness of BufferGel and 0. 5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011; 25: 957–966.
29. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M et al. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010; 376: 1329–1337.
30. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 2010; 37: 745–750.
31. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Nature 2011; 4: 648–657.
32. Abdool Karim Q, Abdool Karim S, Frohlich JA, Grobler AC, Baxter C, Mansoor LE et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168–1174.
33. Marrazzo J, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372: 509–518.
34. CONRAD. FACTS 001: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Young Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection. 2011. Available from https://www.clinicaltrials.gov/ct2/show/NCT01386294.
35. Centre for the AIDS Programme of Research in South Africa. CAPRISA 009: Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression (TOAST). 2011. Available from https://clinicaltrials.gov/ct2/show/NCT01387022term=tenofovir&rank=30.
36. Centre for the AIDS Programme of Research in South Africa. CAPRISA 008: Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services. 2012. Available from https://www.clinicaltrials.gov/ct2/show/NCT01691768.
37. National Institute of Allergy and Infectious Diseases (NIAID). MTN-008: Tenofovir Gel in Pregnancy and Lactation. 2010. Availbale from https://www.clinicaltrials.gov/ct2/show/NCT01136759term=tenofovir&rank=8.
38. CONRAD. A10-114: Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use. 2011. Available from https://www.clinicaltrials.gov/ct2/show/NCT01421368term=tenofovir&rank=28.
39. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S et al. No New HIV infections with increasing use of HIV pre-exposure prophylaxis in a clinical practice setting. Clin Infect Dis, e-pub ahead of print 24 September 2015; doi: 10.1093/cid/civ778.
40. Biswas N, Rodriguez-Garcia M, Shen Z, Crist SG, Bodwell JE, Fahey JV et al. Effects of Tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract. Antimicrob Agents Chemother 2014; 58: 6444–6453.
41. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012; 206: 993–1001.
42. Cahn P, Rolon MJ, Gun AM, Ferrari I, Dibirdik I, Qazi S et al. Preclinical and first-in-human Phase I clinical evaluation of Stampidine, a potent anti-HIV pharmaceutical drug candidate. J AIDS Clinic Res 2012; 3: 138.
43. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 483–488.
44. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416–423.
45. Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis 2015; 211: 1211–1218.
46. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14: 17–27.
47. Kumamoto Y, Iwasaki A. Unique features of antiviral immune system of the vaginal mucosa. Curr Opin Immunol 2012; 24: 411–416.
48. Kell PD, Barton SE, Edmonds DK, Boag FC. HIV infection in a patient with Meyer–Rokitansky–Kuster–Hauser Syndrome. J R Soc Med 1992; 85: 706–707.
49. Miller CJ, Alexander NJ, Vogel P, Anderson J, Marx PA. Mechanism of genital transmission of SIV: a hypothesis based on transmission studies and the location of SIV in the genital tract of chronically infected female rhesus macaques. J Med Primatol 1992; 21: 64–68.
50. Micsenyi AM, Zony C, Alvarez RA, Durham ND, Chen BK, Klotman ME. Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. J Infect Dis 2013; 208: 1756–1767.
51. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74: 6087–6095.
52. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587–597.
53. Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol 2012; 10: e1001448.
54. Puryear WB, Akiyama H, Geer SD, Ramirez NP, Yu X, Reinhard BM et al. Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. PLoS Pathog 2013; 9: e1003291.
55. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7: 375–380.
56. Chang JJ, Woods M, Lindsay RJ, Doyle EH, Griesbeck M, Chan ES et al. Higher expression of several interferonstimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Invest Dermatol 2013; 208: 830–838.
57. Shanmugasundaram U, Critchfield JW, Pannell J, Perry J, Giudice LC, Smith-McCune K et al. Phenotype and functionality of CD4 and CD8 T cells in the upper reproductive tract of healthy premenopausal women. Am J Reprod Immunol 2014; 71: 95–108.
58. Smith JM, Shen Z, Wira CR, Fanger MW, Shen L. Effects of menstrual cycle status and gender on human neutrophil phenotype. Am J Reprod Immunol 2007; 58: 111–119.
59. Okoye AA, Picker LJ. CD4+ T cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013; 254: 54–64.
60. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80: 8236–8247.
61. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4 cell depletion. J Infect Dis 2003; 188: 1794–1803.
62. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009; 23: 1595–1598.
63. Mugo NR, Heff ron R, Donnell D, Wald A, Were EO, Rees H et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011; 25: 1887–1895.
64. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27: 105–113.
65. Ralph LJ, McCoy SI, Shiu K, Padian N. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15: 181–189.
66. Heffron R, Donell D, Rees H, Celum C, Mugo N, Were E et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. Lancet Infect Dis 2012; 12: 19–26.
67. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22: 1909–1917.
68. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2: 1084–1089.
69. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Human Retroviruses 1998; 14: S119–S123.
70. Vishwanathan SA, Guenthner PC, Lin CY, Debord C, Sharma S, Adams DR et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57: 261–264.
71. Goode D, Arvantinou M, Jarl S, Truong R, Derby N, Guerra-Perez N et al. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PloS One 2014; 9: e97767.
72. Fahey JV, Schaefer TM, Channon JY, Wira CR. Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod 2005; 20: 1439–1446.
73. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stiffer SA et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013; 339: 1088–1092.
74. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV. Innate immunity in the human female reproductive tract: Endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 196–211.
75. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458: 1034–1038.
76. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 2013; 110: 6626–6633.
77. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferont K, Asaa-Chapman MM et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013; 10: 146–164.
78. Hotter D, Kirchhoff F, Sauter D. HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 2013; 87: 7160–7165.
79. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009; 83: 10395–10405.
80. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H et al. INTERFEROME v2. 0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013; 41: D1040–D1046.
81. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004; 427: 848–853.
82. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2010; 85: 208–216.
83. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008; 4: e1000231.
84. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006; 80: 9259–9269.
85. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12: 591–601.
86. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H et al. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation- resistant APOBEC3G variant. J Virol 2007; 81: 8236–8246.
87. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013; 502: 559–562.
88. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 2012; 18: 1682–1687.
89. Puigdomenech I, Casartelli N, Porrot F, Schwartz O. SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. J Virol 2013; 87: 2846–2856.
90. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658–661.
91. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Ségéral E et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654–657.
92. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012; 13: 223–228.
93. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009; 139: 499–511.
94. Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 583–591.
95. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245–252.
96. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 2012; 120: 778–788.
97. Sandler GN, Bosinger SE, Estes JD, Zhu RTR, Tharp GK, Boritz E et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511: 601–605.
98. Asmuth DM, Abel K, George MD, Dandekar S, Pollard RB, Miller CJ. Pegylated interferon-a2a treatment of chronic SIV-infected macaques. J Med Primatol 2007; 37: 26–30.
99. Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog P. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004; 84: 331–345.
100. Zirafi O, Kim KA, Roan NR, Kluge SF, Muller JA, Jiang S et al. Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. Sci Transl Med 2014; 6: 262ra157.
101. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131: 1059–1071.
102. Roan NR, Muller JA, Liu H, Chu S, Arnold F, Sturzel CM et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011; 10: 541–550.
103. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13: 491–501.
104. Lisco A, Munawwar A, Introini A, Vanpouille C, Saba E, Feng X et al. Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis 2012; 205: 97–105.
105. Olivier AJ, Masson L, Ronacher K, Walzl G, Coetzee D, Lewis DA et al. Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation. J Infect Dis 2014; 209: 1174–1184.
106. Demers A, Kang G, Ma F, Lu W, Yuan Z, Li Y et al. The mucosal expression pattern of Interferon-epsilon in rhesus macaques. J Leukoc Biol 2014; 96: 1101–1107.
107. Xi Y, Day SL, Jackson RJ, Ranasinghe C. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol 2012; 5: 610–622.
108. D'Cruz OJ, Uckun FM. Vaginal microbicides and their platforms. Expert Opin Drug Deliv 2014; 11: 723–740.